Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tobacco smoking is a preventable cause of morbidity and mortality throughout the world. Very high rates of tobacco smoking are seen in patients with schizophrenia. Importantly, smokers with schizophrenia generally have higher nicotine dependence scores, experience more severe withdrawal symptoms upon smoking cessation, have lower cessation rates than healthy individuals, and suffer from significant smoking-related morbidity and premature mortality compared with the general population. Interestingly, significant disturbances in cholinergic function are reported in schizophrenia patients. The high smoking-schizophrenia comorbidity observed in schizophrenia patients may be an attempt to compensate for this cholinergic dysfunction. Cholinergic neurotransmission plays an important role in cognition and is hypothesized to play an important role in schizophrenia-associated cognitive deficits. In this review, preclinical evidence highlighting the beneficial effects of nicotine and subtype-selective nicotinic receptor agonists in schizophrenia-associated cognitive deficits, such as working memory and attention, is discussed. Furthermore, some of the challenges involved in the development of procognitive medications, particularly subtype-selective nicotinic receptor agonists, are also discussed. Amelioration of schizophrenia-associated cognitive deficits may help in the treatment of schizophrenia-smoking comorbidity by promoting smoking cessation and thus help in the better management of schizophrenia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1259 · Cited by 2,538
Presynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308 · cited 1×
“Finally, neuronal nAChRs can exist as both autoreceptors andheteroreceptors and thus canmodulate the release of numerous neurotransmitters, such as dopamine, norepinephrine, glutamate, g-aminobutyric acid and acetylcholine (Wonnacott, 1997).”
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276 · cited 2×
“%) are reported in patients suffering from schizophrenia (Chapman et al., 2009; de Leon et al., 1995; de Leon and Diaz, 2005; Dome et al., 2010; Hughes et al., 1986; Leonard et al., 2001).”
Grant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1107 · Cited by 1,262 · cited 2×
“Individuals with a psychiatric disorder consume approximately 46% of all cigarettes smoked in the United States (Grant et al., 2004).”
MethodNicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070 · cited 1×
“In the central nervous system, both pre- and post-synaptic localization of nAChRs has been reported, with the majority of nAChR neurotransmission occurring via presynaptically located receptors (Alkondon et al., 1998; McGehee et al., 1995; Nashmi and Lester, 2006).”
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058 · cited 2×
“%) are reported in patients suffering from schizophrenia (Chapman et al., 2009; de Leon et al., 1995; de Leon and Diaz, 2005; Dome et al., 2010; Hughes et al., 1986; Leonard et al., 2001).”
Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
Modes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Schizophrenia, sensory gating, and nicotinic receptors
Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“Decreased expression of a7 nAChRs was found in several brain regions, such as the hippocampus, reticular nucleus of the thalamus, and prefrontal cortex in schizophrenia patients (Court et al., 1999; Freedman et al., 1995; Guan et al., 1999; Olincy and Stevens, 2007).”
Nicotinic Cholinergic Receptor Binding Sites in the Brain: Regulation in Vivo
Schwartz, R. D., & Kellar, K. J. (1983) · Science · doi:10.1126/science.6828889 · Cited by 479 · cited 1×
“Finally, preclinical studies have shown that repeated administration of nicotine upregulates nAChRs (Flores et al., 1992; Schwartz and Kellar, 1983; Yates et al., 1995).”
Structural and functional diversity of native brain neuronal nicotinic receptors
Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., & Zoli, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.024 · Cited by 469
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 3×
“, poverty of speech) in patients with schizophrenia (Freedman et al., 2008).”
InfluentialMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · cited 1×
“N-methyl-D-aspartate receptor dysfunction is hypothesized to be a key player in mediating the pathophysiology of schizophrenia, particularly schizophrenia-associated cognitive deficits (Goff and Coyle, 2001; Konradi and Heckers, 2003).”
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328 · cited 3×
“lack of animal models of cognitive deficits that have predictive validity (Markou et al., 2009).”
Self-citationGrottick, A. J., & Higgins, G. A. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00305-3 · Cited by 240 · cited 2×
“For example, the selective a7 nAChR agonist AR-R17779 did not have beneficial effects on attention in the 5-CSRTT (Grottick and Higgins, 2000; Hahn et al., 2003), suggesting that a7 nAChRs have possibly no role or a limited role in attention.”
Lysakowski, A., Wainer, B. H., Bruce, G., & Hersh, L. B. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90180-2 · Cited by 239 · cited 1×
“…are two brain regions critically involved in cognitive function, and these two brain areas are tightly regulated by extensive cholinergic projections from several forebrain regions (Hasselmo and Sarter, 2011; Lysakowski et al., 1989; Mesulam, 2004; Rye et al., 1984; Sarter et al., 2005).”
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233 · cited 1×
“In contrast, impairments in attention have been reported in a7 nAChR knockout mice in the 5-CSRTT (Hoyle et al., 2006; Young et al., 2007, 2004).”
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1931 · Cited by 230
The cholinergic innervation of the human cerebral cortex.
Mesulam, M.-M. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45004-8 · Cited by 211 · cited 1×
“…are two brain regions critically involved in cognitive function, and these two brain areas are tightly regulated by extensive cholinergic projections from several forebrain regions (Hasselmo and Sarter, 2011; Lysakowski et al., 1989; Mesulam, 2004; Rye et al., 1984; Sarter et al., 2005).”
Hoyle, E., Genn, R. F., Fernandes, C., & Stolerman, I. P. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0549-2 · Cited by 161
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Howe, W. M., Ji, J., Parikh, V., Williams, S., Mocaër, E., Trocmé-Thibierge, C., & Sarter, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.9 · Cited by 150 · cited 1×
“Furthermore, selective a4b2 receptor agonists may be hypothesized to have superior pro-attentional efficacy compared with nicotine (Howe et al., 2010).”
Attentional effects of nicotinic agonists in rats
Hahn, B., Sharples, C. G. V., Wonnacott, S., Shoaib, M., & Stolerman, I. P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00099-6 · Cited by 135 · cited 2×
“For example, the selective a7 nAChR agonist AR-R17779 did not have beneficial effects on attention in the 5-CSRTT (Grottick and Higgins, 2000; Hahn et al., 2003), suggesting that a7 nAChRs have possibly no role or a limited role in attention.”
Levin, E. D., & Rezvani, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.019 · Cited by 129 · cited 1×
“Interestingly, antipsychotics have anticholinergic properties and can affect nAChR expression (Grinevich et al., 2009; Levin and Rezvani, 2007; Singhal et al., 2007; Terry et al., 2003).”
Wilens, T. E., Verlinden, M. H., Adler, L. A., Wozniak, P. J., & West, S. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.029 · Cited by 123
(1993) · doi:10.1016/0376-8716(93)90041-n · Cited by 77 · cited 1×
“Another hypothesis states that acute nicotine can produce dysphoric effects that may interfere with performance on attentional tasks (Heishman et al., 1993).”
Yates, S. L., Bencheri, M., Fluhler, E. N., & Lippiello, P. M. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02100-0 · Cited by 65 · cited 1×
“Finally, preclinical studies have shown that repeated administration of nicotine upregulates nAChRs (Flores et al., 1992; Schwartz and Kellar, 1983; Yates et al., 1995).”
Cited by
Neuromodulation by acetylcholine: examples from schizophrenia and depression
Higley, M. J., & Picciotto, M. R. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.06.004 · Cited by 184
“Epidemiological studies have long shown that schizophrenics exhibit higher rates of tobacco smoking than the general population, suggesting that patients may use nicotine (an agonist of nAChRs) for self-medication [31,32].”
Picciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157
Tang, A.-H., Karson, M. A., Nagode, D. A., McIntosh, J. M., Uebele, V. N., Renger, J. J., Klugmann, M., Milner, T. A., & Alger, B. E. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2781-11.2011 · Cited by 92
Caldirola, D., Daccò, S., Grassi, M., Citterio, A., Menotti, R., Cavedini, P., Girardi, P., & Perna, G. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07985 · Cited by 27
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
Metadata
- Authors
- D’Souza, M. S., & Markou, A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 62
- Issue
- 3
- Pages
- 1564-1573
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2039714278
- Cited by
- 120
- References
- 30
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.